Mixed Bag of Interstitial Lung Diseases at Tertiary Care Centre
DOI:
https://doi.org/10.61841/06tap184Keywords:
ILD, DPLD, Idiopathic Interstitial Pneumonia, HRCT Thorax, IPF, NSIP, CTD-ILD, HPAbstract
Context: ILD or DPLD is a heterogeneous group of disorders that is characterized by varying degrees of inflammation and fibrosis in the lung parenchyma. This study is being done to analyze the spectrum of ILD, their common clinical presentations, radiological features, and causes so that it may help in a better understanding of the disease in the Indian context.
Aims: To study the underlying causes of ILD in patient diagnosis based on clinical history & HRCT.
Settings and Design: We conducted a retrospective study based on the available departmental data records of 41 ILD patients from October 2017 to October 2019 at our tertiary care center.
Methods and Material: Patients with chief complaints of dyspnea and cough with a chest radiograph and HRCT thorax suggestive of ILD were collected for the study, and statistical analysis was done.
Statistical analysis used: SPSS computer software version 20.0.
Results: Forty-one patients were enrolled. The mean age of presentation was 55.75 years. There was male predominance seen. Progressive dyspnea (90.24%) and dry cough (63.4%) were the most common symptoms in ILD patients. On examination, Velcro crackles, clubbing, & restrictive pattern on spirometry were predominantly found. IPF was the most common (46.43%) ILD, followed by non-IPF IIPs, connective tissue disease-related ILD, chronic HP, sarcoidosis, and smoking-related ILD, which were diagnosed in 19.51%, 17.07%, 7.32%, 7.32%, and 2.44% of the subjects, respectively.
Conclusions: IPF was the most common IIP found, followed by NSIP. CTD & chronic HP were found as definitive causes in some, which changed the treatment & prognosis.
Downloads
References
[1] Dhooria S, Agarwal R, Sehgal IS, Prasad KT, Garg M, Bal A, et al. (2018) Spectrum of interstitial lung
Diseases at a tertiary center in a developing country: A study of 803 subjects. PLoS ONE 13(2): e0191938
[2] Singh S, Collins BF, Sharma BB, Joshi JM, Talwar D, Katiyar S, Singh N, Ho L, Samaria JK, Bhattacharya
P, Gupta R. Interstitial lung disease in India. Results of a prospective registry. American journal of
Respiratory and critical care medicine. 2017 Mar 15; 195(6):801-13.
[3] Subhash HS, Ashwin I, Solomon SK, David T, Cherian AM, Thomas K. A comparative study on idiopathic
pulmonary fibrosis and secondary diffuse parenchymal lung disease. Indian J Med Sci. 2004; 58(95): 186–
8.
[4] Maheshwari U, Gupta D, Aggarwal AN, Jindal SK. Spectrum and diagnosis of idiopathic pulmonary
fibrosis. Indian Journal of Chest Diseases and Allied Sciences. 2004 Jan 1; 46(1):23-6.
[5] Sen T, Udwadia ZF. Retrospective study of interstitial lung disease in a tertiary care center in India. The
Indian journal of chest diseases & allied sciences. 2010 Oct; 52(4): 207.
[6] Das V, Desai U, Joshi JM. Clinical profile of interstitial lung disease at a tertiary care center, India.
Pneumon. 2017 Jan 1; 30(1):17-23.
[7] Muhammed Shafeeq K, Anithakumari K, Fathahudeen A, Jayaprakash B, Ronaid Win B, Sreekala RS,
Sanjeev Nair MM. Aetiology and clinic-radiological profile of interstitial lung disease in a tertiary care
Centre. Cough. 2011; 63: 90-0.
[8] Agrawal MK, Kumar A, Agrawal R, Rana R. To study the significance of HRCT over Chest x-ray in the
diagnosis of interstitial lung diseases. Journal of Evolution of Medical and Dental Sciences. 2019 Jan 14;
8(2): 94-9.
[9] Badarkhe-Patil P, Kawade D, Titare P, Rote-Kaginalkar V. HRCT Assessment of Interstitial Lung
Diseases. Int J Contemp Med Res. 2016; 3(8): 2426–30.
[10] Devi HJG, Halappa S, Davis D, Jain A. Interstitial Lung Disease : A Tertiary Care Center Experience.
IOSR J Dent Med Sci. 2016; 15(1): 5–8.
[11] Singh V, Sharma BB. Laying the ground for research of interstitial lung disease in our country: ILD India
registry. Lung India: official organ of Indian Chest Society. 2014 Oct; 31(4):320.
[12] Je M, Hogg JC, Mcdonough JE, Columbia B, Cooper JD, Gefter WB, et al. Fishman's pulmonary disease
& disorders. 5th editio. 1697 p.
[13] Raghu G, Mehta S. Interstitial lung disease (ILD) in India: Insights and lessons from the prospective,
landmark ILD-India registry. Lung India: official organ of Indian Chest Society. 2016 Nov; 33(6):589.
[14] Agarwal, Vikas, et al. "Clinical profile of headache from a tertiary care center in eastern India." International journal of general medicine and pharmacy (IJGMP) 2.3 (2013): 9-14.
[15] Mahashur AA, Dave KM, Kinare SG, Kamat SR, Shetye VM, Kolhatkar VP. Diffuse fibrosing alveolitis: Indian experience. Lung India. 1983 Aug 1; 1(5):171.
[16] Sen T, Udwadia ZF. Retrospective study of interstitial lung disease in a tertiary care center in India. The Indian Journal of Chest Diseases & Allied Sciences. 2010 Oct; 52(4):207.
[17] Nagai S, Kitaichi M, Itoh H, Nishimura K, Izumi T, Colby TV. Idiopathic nonspecific interstitial
Pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. European Respiratory
Journal. 1998 Nov 1; 12(5):1010-9.
[18] Chandrika, K.B. "Need and intervention of social workers in public health care services and social
development." International Journal of Humanities and Social Sciences 4.1 (2015): 57-62.
[19] Johnston ID, Prescott RJ, Chalmers JC, Rudd RM. British Thoracic Society study of cryptogenic fibrosing
Alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research
Committee of the British Thoracic Society. Thorax. 1997 Jan 1; 52(1):38-44.
[20] Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK,
Morell F, Flaherty KR. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT
clinical practice guideline. American journal of respiratory and critical care medicine. 2018 Sep 1; 198(5):
e44-68.
[21] Huang H, Dai HP, Kang J, Chen BY, Sun TY, Xu ZJ. Double-blind randomized trial of pirfenidone in
Chinese idiopathic pulmonary fibrosis patients. Medicine. 2015 Oct; 94(42).
[22] Afolabi, Adeola Folashade, Adeniyi Olanipekun Fasanu, and Adewale Samson Adeyemi. "Comparison of
ELISA and rapid screening tests for the diagnosis of HIV in high-risk individuals." Infection 1 (2014): 3.
[23] Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ. Idiopathic pulmonary fibrosis in BRIC countries:
the cases of Brazil, Russia, India, and China. BMC Medicine. 2015 Dec; 13(1):237.
[24] Kundu S, Mitra S, Ganguly J, Mukherjee S, Ray S, Mitra R. Spectrum of diffuse parenchymal lung
diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern
Indian experience. Lung India: official organ of Indian Chest Society. 2014 Oct; 31(4): 354.
[25] Jasim, Wisam Abdullah, and Hussein Imran Mousa. "Neurosurgical Congenital Anomalies in Basrah
Sociodemographic Review." International Journal of Medicine and Pharmaceutical Science (IJMPS) 8. 2,
Apr 2018, 33-38
[26] Singh S, Collins BF, Sharma BB, Joshi JM, Talwar D, Katiyar S, Singh N, Ho L, Samaria JK, Bhattacharya
P, Chaudhari S. Hypersensitivity pneumonitis: Clinical manifestations—Prospective data from the interstitial
lung disease-India registry. Lung India: official organ of Indian Chest Society. 2019 Nov; 36(6):476.
[27] Thomeer MJ, Costabel U, Rizzato G, Poletti V, Demedts M. Comparison of registries of interstitial lung
diseases in three European countries. European Respiratory Journal. 2001 Jul 1; 18(32 suppl):114s-8s.
[28] Owonikoko, Kola M., et al. "Assessment of Blood Transfusion Practices at Caesarean Section in a
Teaching Hospital in South-western Nigeria." International Journal of Medicine and Pharmaceutical
Sciences 4.6 (2014): 69-76.
[29] Levi Y, Israeli-Shani L, Kuchuk M, Shochet GE, Koslow M, Shitrit D. Rheumatological assessment is
important for interstitial lung disease diagnosis. The Journal of rheumatology. 2018 Nov 1; 45(11):1509-
14.
[30] Chan C, Ryerson CJ, Dunne JV, Wilcox PG. Demographic and clinical predictors of progression and
Mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study. BMC
Pulmonary Medicine. 2019 Dec 1; 19(1):192.
[31] Das, P.C., et al. "Dementia care in India: Issues & prospects." Int J Med Pharm Sci 4 (2014): 29-36.
[32] Agrawal A, Thyagarajan B, Ceniza S, Hasan Yusuf S. Interstitial Lung Disease of the UIP Variant as the
Only Presenting Symptoms of Rheumatoid Arthritis. Case reports in pulmonology. 2015.
[33] Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Patterns of interstitial lung disease
and mortality in rheumatoid arthritis. Rheumatology. 2017 Mar 1; 56(3):344-50.
[34] Singh P, Thakur B, Mohapatra AK, Padhan P. Clinical features and outcome of acute exacerbation in
Connective tissue disease‐ disease‐associated interstitial lung disease: A single‐ single‐center study from India.
International journal of rheumatic diseases. 2019 Sep; 22(9): 1741-5.
[35] Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. American journal of respiratory and critical care medicine. 2015 Jul 15; 192(2): e3-19.
[36] Cottin V. Interstitial lung disease. Eur Respir Rev. 2013; 229(127): 26-32
[37] María Molina-Molina, Myriam Aburto, Orlando Acosta, Julio Ancochea, José Antonio Rodríguez-Portal, Jaume Sauleda, Carlos Lines & Antoni Xaubet (2018) Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis, Expert Review of Respiratory Medicine, 12:7, 537-539.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
